ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2430

For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4

Isabelle Auger1, Nathalie Balandraud2 and Jean Roudier3, 1INSERM UMRs 1097, Marseille, France, 2Rheumatology, APHM, Marseilles, France, 3Arthrites auto-immunes, INSERM UMRs 1097, Marseille, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: citrulline, human leukocyte antigens (HLA), immunity and rheumatoid arthritis (RA), PAD

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

HLA-DRB1 genotypic risk to develop ACPA positive RA correlates with capability of encoded HLA-DRB1 chains to bind Peptidyl Arginyl Deiminase (PAD4) peptides, not citrullinated Fibrinogen peptides.

Background/Purpose: The risk to develop ACPA positive RA is controlled by HLA-DRB1 genotypes. This may be due to the binding of citrullinated peptides by HLA-DRB1 chains encoded by each genotype. Alternatively, we propose that binding of peptides from PAD4 by HLA-DRB1 allows to help the production of antibodies to citrullinated epitopes on any protein bound by PAD4.

Methods: We studied the binding of 65 overlapping peptides from PAD4 and 96 overlapping peptides from the Fibrinogen alpha and beta chains under their native or citrullinated form to purified HLA-DRB1*0401, *0404, *0101, *0402, *0701 by ELISA. We calculated a likelihood of binding at least one peptide from PAD4, native Fibrinogen or citrullinated Fibrinogen by the two HLA-DRB1 chains encoded by each possible genotype and compared it with the risk carried by the same genotype to develop ACPA positive RA.

Results: HLA-DRB1 genotypic risks to develop RA correlate with likelyhood to bind PAD4 peptides (P=0.06, Pearson’s), not citrullinated Fibrinogen peptides (p >0,6 and p>0.9) (Figure 1).

Conclusion: Comparison of binding properties of HLA-DRB1 molecules in each of 12 genotypes to PAD4 or native or citrullinated Fibrinogen peptides suggests restriction of PAD4 presentation may explain the association of HLA-DRB1 alleles with ACPA positive RA

Figure 1 : OR to develop RA correlates with probability to bind at least one peptide from PAD4, not Fibrinogen or citrullinated Fibrinogen


Disclosure: I. Auger, None; N. Balandraud, None; J. Roudier, None.

To cite this abstract in AMA style:

Auger I, Balandraud N, Roudier J. For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4 [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/for-each-hla-drb1-genotype-the-likelihood-to-develop-ra-correlates-with-the-probability-of-binding-at-least-a-peptide-from-pad4/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/for-each-hla-drb1-genotype-the-likelihood-to-develop-ra-correlates-with-the-probability-of-binding-at-least-a-peptide-from-pad4/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology